Asexual reproduction

iQIYI Hosts M2VOC Challenge with 6 Papers Included in ICASSP2021

Retrieved on: 
Saturday, June 19, 2021

M2VoC, an ICASSP2021 Signal Processing Grand Challenge, aimed at providing a common sizable dataset and a fair test bed for benchmarking voice cloning tasks.

Key Points: 
  • M2VoC, an ICASSP2021 Signal Processing Grand Challenge, aimed at providing a common sizable dataset and a fair test bed for benchmarking voice cloning tasks.
  • The M2VoC had two main tracks, including one for teams working from limited samples and one for very limited samples.
  • As the world's first Multi-speaker Multi-style Voice Cloning Challenge, M2VoC brought together leading teams from industry and academia at the cutting edge of voice cloning technology.
  • A total of 18 related papers were included in the Challenge, among which 6 papers were included in ICASSP2021.

Allied Corp Expands Cannabis Production and Inventory Capacity

Retrieved on: 
Thursday, June 3, 2021

Also included in this expansion are planned upgrades to electrical and water filtration systems along with expanded drying and packaging capacity.

Key Points: 
  • Also included in this expansion are planned upgrades to electrical and water filtration systems along with expanded drying and packaging capacity.
  • Our production facilities can accommodate 12,000 plants in vegetative stage and 10,000 cloned plants in the propagation stage.
  • With this progress, Allied intends to provide long-standing, consistent supply and demonstrate scale to the international marketplace, said Calum Hughes, CEO of Allied.
  • Allied Corp. is an international heath company with a mission to address todays medical issues by researching, creating and producing targeted health solutions.

One World Pharma Announces First Sale of Cuttings in Colombia

Retrieved on: 
Monday, April 26, 2021

The ability to sell cuttings is mutually advantageous to OWP\xe2\x80\x99s customers and the Company.\xc2\xa0 While many cultivators prefer and are comfortable with purchasing and planting seeds, many would prefer the time-to-market advantage and elimination of germination risk by buying plantlets.

Key Points: 
  • The ability to sell cuttings is mutually advantageous to OWP\xe2\x80\x99s customers and the Company.\xc2\xa0 While many cultivators prefer and are comfortable with purchasing and planting seeds, many would prefer the time-to-market advantage and elimination of germination risk by buying plantlets.
  • One World Pharma has developed an effective means by which to grow genetically superior cuttings at scale.\nTo that end, OWP cuttings can be grown in a 20 day cycle with a current capacity of approximately 9,000 per cycle, with an expected scaling to a capacity of 18,000 cuttings per cycle by year end.\nThis new ICA approval builds on previous CBD and THC strain approvals and is an effective confirmation of the importance of the Company\xe2\x80\x99s seed license.
  • OWP offers a reliable and sustainable supply chain for chemical formulators, food & beverage producers as well as beauty product manufacturers worldwide.
  • The company maintains corporate offices in Las Vegas, NV and Bogota Colombia and a facility in Popayan, Colombia.\n'

A New Platform for Clinical Gene-Editing of iPSCs to Make Clonal Cell Banks, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, February 2, 2021

Current cloning approaches include colony picking and two rounds of cloning, which is very time-consuming.

Key Points: 
  • Current cloning approaches include colony picking and two rounds of cloning, which is very time-consuming.
  • Solentim now presents a platform combination of instrumentation and soluble matrix for the high-efficiency, high-viability single-cell cloning of iPSCs to form the Master Cell Bank.
  • This platform will allow for groups to more easily perform clinical gene-editing and cloning of iPSCs across a broader range of cell therapies.
  • For more information, or to register for this event, visit A New Platform for Clinical Gene- Editing of iPSCs to Make Clonal Cell Banks.

iQIYI Holds World's First Low-Resource Voice Cloning Challenge to Accelerate Development of AI Voice Technology

Retrieved on: 
Tuesday, December 15, 2020

iQIYI released detailed guidelines for M2VoC, the first low-resource voice cloning challenge in the world, on 27 November.

Key Points: 
  • iQIYI released detailed guidelines for M2VoC, the first low-resource voice cloning challenge in the world, on 27 November.
  • iQIYI hopes that M2VoC will help to address these issues and accelerate the development of AI voice technology.
  • Through this challenge, iQIYI hopes to team up with talented researchers and build solutions for low-resource voice cloning with advanced deep-learning technology and multi-stylistic voice morphing technology.
  • The Company also anticipates that M2VoC will further elevate the interactive experience of video and drive the development and application of voice cloning technology.

One World Pharma Enters Agreement and LOI with BIOTROPICAL for Up to 600,000 Cuttings

Retrieved on: 
Friday, October 16, 2020

Additionally, the Companies have entered into a Letter of Intent (LOI) for BIOTROPICAL to purchase up to 600,000 cuttings from One World Pharma.

Key Points: 
  • Additionally, the Companies have entered into a Letter of Intent (LOI) for BIOTROPICAL to purchase up to 600,000 cuttings from One World Pharma.
  • A plant cutting is a part of a plant that is used in horticulture for vegetative (asexual) propagation, in this instance cannabis production.
  • Under the terms of the LOI, One World Pharma would purchase the entire harvest from BIOTROPICAL.
  • After the initial 30,000 cuttings, BIOTROPICAL plans to expand its operation up to 600,000 cuttings by the second quarter of 2021.

Rising Levels of Investment Poured in by Key Players to Help Global Biotherapeutics Cell Line Development Market Witness Promising CAGR of ~7% from 2020 to 2030

Retrieved on: 
Monday, June 8, 2020

In terms of process, the global biotherapeutics cell line development can be segmented into single cell cloning and transfection & selection.

Key Points: 
  • In terms of process, the global biotherapeutics cell line development can be segmented into single cell cloning and transfection & selection.
  • Based on the CLD option, the global biotherapeutics cell line development market is segmented into hybrid, do it yourself, outsource, and in-house.
  • Request a sample of the study
    There are five key regions of the global biotherapeutics cell line development market viz.
  • Global Biotherapeutics Cell Line Development Market: Segmentation
    Biotherapeutics Cell Line Development Market, by Process

Rising Levels of Investment Poured in by Key Players to Help Global Biotherapeutics Cell Line Development Market Witness Promising CAGR of ~7% from 2020 to 2030

Retrieved on: 
Monday, June 8, 2020

In terms of process, the global biotherapeutics cell line development can be segmented into single cell cloning and transfection & selection.

Key Points: 
  • In terms of process, the global biotherapeutics cell line development can be segmented into single cell cloning and transfection & selection.
  • Based on the CLD option, the global biotherapeutics cell line development market is segmented into hybrid, do it yourself, outsource, and in-house.
  • Request a sample of the study
    There are five key regions of the global biotherapeutics cell line development market viz.
  • Global Biotherapeutics Cell Line Development Market: Segmentation
    Biotherapeutics Cell Line Development Market, by Process

eGenesis Strengthens Production Capabilities with Acquisition of ICBiotec

Retrieved on: 
Wednesday, May 20, 2020

ICB is one of the few companies in the U.S. with advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain.

Key Points: 
  • ICB is one of the few companies in the U.S. with advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain.
  • The acquisition will provide eGenesis with full control of its xeno-organ supply chain.
  • eGenesis is committed to advancing therapies for patients in need of organ, tissue, and cell transplants, said Paul Sekhri, President and Chief Executive Officer of eGenesis.
  • The acquisition of ICB is a key part of our strategic development plan and enables us to vertically integrate our research, cloning, and production capabilities.

TERC Hosts 6th Annual STEM for All Video Showcase, Funded by NSF, to Broaden Participation and Access to STEM Education on May 5-12

Retrieved on: 
Tuesday, May 5, 2020

All are welcome to view, discuss, and vote for favorites from May 5-12.

Key Points: 
  • All are welcome to view, discuss, and vote for favorites from May 5-12.
  • "The online STEM for All Video Showcase will fill a void, with so many STEM educational conferences having been canceled due to COVID-19.
  • Despite challenges faced by school and institutional closures, 695 presenters and co-presenters have come together to present short video narratives of their cutting-edge work to improve STEM education.
  • Last year's STEM for AllVideo Showcase is still being accessed, and to date has had over 76,000 unique visitors from 181 countries.